CDC14B is a favorable biomarker for recurrence and prognosis of GBM.

Abstract

Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults. The treatment options of GBM are quite few and the prognosis of GBM is very dismal. Identifying the effective and prognostic biomarker is important for molecular classification and individual treatment of patients. CDC14 is a conserved dual specificity phosphatase functioning mainly in mitosis and DNA respiration. The expression and function of CDC14 family in tumor progression is still elusive. In our study, we established a retrospective GBM cohort consisting of 135 patients who underwent the surgery and received standard treatment therapy. We compared the expression of CDC14A and CDC14B in GBM and tumor-adjacent tissues by retrieving data from TCGA and qPCR. With immunohistochemistry (IHC), we detected the expression of CDC14B in the cohort, and analyzed the correlation between CDC14B and clinicopathological factors by chi-square test. The significance of CDC14B on GBM recurrence and prognosis was assessed by univariate and multivariate analyses. CDC14B, but not CDC14A, had a higher expression in GBM tissues than in tumor-adjacent tissues. High CDC14B was correlated with high progression-free survival (PFS) rate and overall survival (OS) rate of GBM. In the Cox-regression model, CDC14B was an independent and favorable biomarker indicating low risk of recurrence and GBM-related death. High CDC14B is correlated with high GBM PFS and OS rate, and CDC14B is an independent biomarker of GBM, indicating low recurrence and favorable prognosis. Our study reveals a new biomarker of GBM which could indicate the recurrence and prognosis of GBM. This may help stratify the high-risk patients and modify the prognostic assessment based on molecular features.